Isotretinoin use and subsequent depression and suicide: Presenting the evidence

American Journal of Clinical Dermatology

Volumn 4, Issue 7, 2003, Pages 493-505

  Hull, Peter R ^a,b   D'Arcy, Carl ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CORTICOSTEROID; ETRETINATE; FENFLURAMINE; HYPOCHOLESTEROLEMIC AGENT; ISOTRETINOIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; RANITIDINE; RETINOIC ACID; RETINOID; RETINOL; SIMVASTATIN; VERAPAMIL;

AUSTRALIA; BIPOLAR DISORDER; BODY DYSMORPHIC DISORDER; CANADA; DEPRESSION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; INFORMED CONSENT; IRELAND; MEDICAL LITERATURE; MOOD DISORDER; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RELIABILITY; REVIEW; SKIN DISEASE; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; SUICIDE; SUICIDE ATTEMPT; SYMPTOMATOLOGY; VALIDATION PROCESS;

EID: 0037766653     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304070-00005     Document Type: Review

References (83)

1. Meadows M. The power of accutane: the benefits and risks of a breakthrough ache drug. FDA Consum 2001; 35: 18-23
2. Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 2002; 46: 505-9
3. US Food and Drug Administration (FDA) Talk Paper. FDA announces changes to the risk management program to prevent birth defects caused by Accutane [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01113.html. [Accessed 2003 May 21]
4. Bull J. Report before the Committee On Government House Reform, US House of Representatives: December 5, 2000 [online]. Available from URL: http://www.hhs.gov/asl/testify/t001205.html. [Accessed 2003 May 21].
5. US Food and Drug Administration (FDA). Dermatologic Drugs Advisory Committee (Accutane) transcripts [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/accutane.htm. [Accessed 2003 May 21]
6. Roche Pharmaceuticals. Our products: Accutane (isotretinoin): complete product information [online]. Available from URL: http://www.rocheusa.com/products/accutane/pi.pdf. [Accessed 2003 May 26]
7. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol 2001; 45: S168-75
8. O'Donnell J. Overview of existing research and information linking isotretinoin (Accutane), depression, psychosis, and suicide. Am J Ther 2003; 10: 148-59
9. Accutane/Roaccutane Action Group. Accutane/Roaccutane Action Group homepage [online]. Available from URL: http://www.roaccutaneaction.com/index.htm. [Accessed 2003 May 21]
10. Stupak B. Accutane [online]. Available from URL: http://www.house.gov/stupak/accutane.htm. [Accessed 2003 May 21]
11. Rothman KJ. Greenland S. Causation and causal inference. Rothman KJ, Greenland S, editors. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998: 7-28
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994: 327
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994: 335
14. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77-100
15. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1977; 1: 385-401
16. Goldberg D, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-45
17. Hamilton M. The Hamilton Rating Scale for Depression. Sartorius N, Ban T, editors. Assessment of depression. Berlin: Springer-Verlag, 1986: 143-52
18. Robins LN, Helzer JE, Croughan J, et al. National Institute of mental health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981; 38: 381-9
19. World Health Organization. Composite International Diagnostic Inventory (CIDI) Version 2.1. Geneva: WHO, 1997
20. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders, (SCID-I), clinician version. Washington, DC: American Psychiatric Press Inc, 1997
21. Wing JK, Cooper JE, Sartorius N. The description and classification of psychiatric symptoms: an instruction manual for the PSE and CATEGO system. London: Cambridge University Press, 1974
22. Statistics Canada. National Population Health Survey - Household Component, Longitudinal [online]. Available from URL: http://stcwww.statcan.ca/english/sdds/3225.htm. [Accessed 2003 May 21]
23. Patten SB. Incidence of major depression in Canada. CMAJ 2000; 163: 714-5
24. Statistics Canada. Mortality: summary list of causes, 1997-SHELF TABLES. CAT. No 84F0209XPB. Ottawa: Statistics Canada, 1999
25. Regier DA, Narrow WE, Rae DS, et al. The de facto mental and addictive disorders service system: epidemiological catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85-94
26. Narrow WE. One-year prevalence of mental disorders, excluding substance use disorders. in the US: NIMH ECA prospective data. Population estimates based on US Census estimated residential population age 18 and over on July, 1998. Cited from URL: http://www.nimh.nih.gov/publicat/numbers.cfm. [Accessed 2003 May 18]
27. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. National Vital statistics Report, 47 (19). Hyattsville (MD): National Center for Health Statistics, 1999. DHHS Publication No. 99-1220
28. Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol 1991; 8: 185-8
29. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol 1995; 32: S23-30
30. Shuster S, Fisher GH, Harris E, et al. The effect of skin disease on self image [proceedings]. Br J Dermatol 1978; 99 Suppl. 16: 18-9
31. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992; 17: 1-3
32. Motley RJ, Finlay AY. How much disability is caused by ache? Clin Exp Dermatol 1989; 14: 194-8
33. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-50
34. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol 1997; 137: 246-50
35. Macdonald-Hull S, Cunliffe WJ, Hughes BR. Treatment of the depressed and dysmorphophobic acne patient. Clin Exp Dermatol 1991; 16: 210-1
36. Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom 1997; 66: 63-73
37. Whitlock FA, Evans LE. Drugs and depression. 1978; 15: 53-71
38. Patten SB, Love EJ. Drug-induced depression: incidence, avoidance and management. Drug Saf 1994; 10 (3): 203-19
39. Australian Adverse Drug Reaction Bulletin. Depression: could it be the drug? [online]. Available from URL: http://www.health.gov.au/tga/docs/html/aadrbltn/aadr9802.htm#dep [Accessed 2003 Apr 16]
40. Patten SB, Lamarre CJ. Can drug-induced depressions be identified by their clinical features. Can J Psychiatry 1992; 37: 213-5
41. Patten SB, Love EJ. Can drugs cause depression? A review of the evidence. J Psychiatry Neurosci 1993; 18: 92-102
42. Hazen PG, Carney JF, Walker AE, et al. Depression: a side effect of 13-cis-retinoic acid therapy. J Am Acad Dermatol 1983; 9: 278-9
43. Scheinman PL, Peck GL, Rubinow DR, et al. Acute depression from isotretinoin. J Am Acad Dermatol 1990; 22: 1112-4
44. Duke EE, Guenther L. Psychiatric reactions to the retinoids. Can J Dermatol 1992; 5: 467
45. Byrne A, Hnatko G. Depression associated with isotretinoin therapy [letter]. Can J Psychiatry 1995; 40: 567
46. Bravard P, Krug M, Rzeznick JC. Isotretinoin and depression: care is needed [letter]. Nouv Dermatol 1993; 12: 215
47. Gatti S, Serri F. Acute depression from isotretinoin [letter]. J Am Acad Dermatol 1991; 25: 132
48. Burket JM, Storrs FJ. Nodulocystic infantile ache occurring in a kindred of steatocystoma. Arch Dermatol 1987; 123: 432-3
49. Aubin S, Lorette G, Muller C, et al. Massive isotretinoin intoxication. Clin Exp Dermatol 1995; 20: 348-50
50. Lindemayr H. Isotretinoin intoxication in attempted suicide. Acta Derm Venereol 1986; 66: 452-3
51. Hepburn NC. Deliberate self-poisoning with isotretinoin. Br J Dermatol 1990; 122: 840-1
52. Ng CH, Tamm MM, Hook SJ. Ache, isotretinoin treatment and depression. World J Biol Psychiatry 2001; 2: 159-61
53. Cott AD, Wisher KL. Isotretinoin treatment of a woman with bipolar disorder [letter]. J Clin Psychiatry 1999; 60: 407-8
54. Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis 1984; 33: 484-9
55. Bigby M, Stern RS. Adverse reactions to isotretinoin: a report from the adverse drug reaction reporting system. J Am Acad Dermatol 1988; 18: 543-52
56. Hull PR, Demkiw-Bartel C. Isotretinoin use in ache: prospective evaluation of adverse events. J Cutan Med Surg 2000; 4: 66-70
57. Hoffmann-La Roche. Briefing Information: Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration, Gaithersburg (MD), Sept. 19 2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3639b1.htm. [Accessed 2003 Apt 16]
58. Nelson RC. Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration. Gaithersburg (MD), Sept. 19 2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3639t2.rtf Page 37. [Accessed 2003 Apt 16]
59. Jacobs D. Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration, Gaithersburg (MD), Sept. 19 2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3639t2.rtf Page: 45. [Accessed 2002 Jun 21]
60. Pitts MR. Positive rechallenge cases of accutane-associated depressive symptoms: Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration, Gaithersburg (MD), Sept. 19 2000 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/slides/3639s2i.pdf. [Accessed 2003 Apr 16]
61. Wysowski DK. Summary of reported cases of depression and suicide in US Accutane treated patients. Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration, Gaithersburg, Md, Sept 19 2000 [online]. Available at URL: http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3639t2.rtf page 122. [Accessed 2003 Apt 16]
62. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45: 515-9
63. Wysowski DK, Pitts MR, Beitz J. Depression and suicide in patients treated with isotretinoin [letter]. N Engl J Med 2001; 344: 460
64. Eaton WW, Kramer M, Anthony JC, et al. The incidence of specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1989; 79: 163-78
65. Wray CM. Accutane and depression. Canadian Adverse Drug Reaction Newletter 1999; 9:1-2 [online]. Available from URL: http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/publicat/ adrv9n1_e.pdf. [Accessed 2003 May 21]
66. Wooltorton E. Accutane (isotretinoin) and psychiatric adverse effects. Can Med Assoc J 2003; 168 (1): 66
67. Australian Adverse Drug Reactions Bulletin. Depression with isotretinoin [online]. Available from URL: http://www.health.gov.au/tga/docs/html/aadrbltn/aadr9808.htm#isot. [Accessed 2003 Apt 16]
68. Irish Medicines Board. Drug safety newletter [online]. Available from URL: http://www.imb.ie/pubs/drugnews/news8.pdf. [Accessed 2002 Jun 21]
69. O'Connell K. Dermatologic and ophthalmic drugs advisory committee to the food and drug administration [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3639t2.rtf. [Accessed 2003 Apr 16]
70. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231-6
71. Rawson Nigel. [personal communication]. 2002
72. Wysowski DK. Methodological limitations of the study "Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide" [letter]. Arch Dermatol 2001; 137: 1102
73. Neary MP, Klaskala W, McLane J, et al. Epidemiological study of adverse events in Accutane users and matched non-users: retrospective analysis of major US health plan claims database. 17th International Conference on Pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2001; 10: S141
74. Bendich A, Langseth L. Safety of vitamin A. Am J Clin Nutr 1989; 49: 358-71
75. Restak RM. Pseudotumor cerebri, psychosis, and hypervitaminosis A. J Nerv Ment Dis 1972; 155: 72-6
76. McCance-Katz EF, Price LH. Depression associated with vitamin A intoxication. Psychosomatics 1992; 33: 117-8
77. Stuttgen G. Oral vitamin A acid therapy. Acta Derm Venereol Suppl (Stockh) 1975; Suppl. 74: 174-9
78. Henderson CA, Highet AS. Depression induced by etrinate [letter]. BMJ 1989; 298: 96
79. Borbujo MJM, Casado JM, Garijo LMB, et al. Efecto secundario inusual por etretinato [An unusual secondary effect of etretinate]. Medicina Clinica 1987; 89: 577
80. Rubinow DR, Peck GL, Squillace KM, et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987: 17: 25-32
81. Newton JN, Mallon E, Klassen A, et al. The effectiveness of ache treatment: an assessment by patients of the outcome of therapy. Br J Dermatol 1997; 137: 563-7
82. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of ache and the effect of treatment with isotretinoin. Br J Dermatol 1999; 140: 273-82
83. Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology 1997; 195 Suppl. 1: 15-21